Gainers

• Akanda (NASDAQ:AKAN) stock increased by 49.9% to $15.3 during Thursday's pre-market session. The market value of their outstanding shares is at $5.4 million.
• West Pharmaceutical Servs (NYSE:WST) shares moved upwards by 17.34% to $322.0. The market value of their outstanding shares is at $19.7 billion. As per the news, the Q1 earnings report came out today.
• cbdMD (AMEX:YCBD) stock moved upwards by 16.13% to $1.08. The company's market cap stands at $9.7 million.
• INVO Fertility (NASDAQ:IVF) shares increased by 10.67% to $2.49. The company's market cap stands at $34.0 million.
• Dr Reddy's Laboratories (NYSE:RDY) shares increased by 7.63% to $13.82. The market value of their outstanding shares is at $10.6 billion.
• InspireMD (NASDAQ:NSPR) stock rose 7.57% to $1.42. The company's market cap stands at $61.7 million.

Losers

• Axe Compute (NASDAQ:AGPU) shares decreased by 23.3% to $6.71 during Thursday's pre-market session. The company's market cap stands at $29.6 million.
• Altimmune (NASDAQ:ALT) shares fell 17.3% to $2.87. The market value of their outstanding shares is at $451.4 million.
• Medpace Holdings (NASDAQ:MEDP) shares decreased by 17.21% to $421.0. The market value of their outstanding shares is at $14.4 billion. As per the press release, Q1 earnings came out yesterday.
• Icecure Medical (NASDAQ:ICCM) shares fell 12.99% to $0.31. The market value of their outstanding shares is at $29.0 million.
• SILO Pharma (NASDAQ:SILO) stock fell 12.22% to $0.5. The company's market cap stands at $9.2 million.
• SciSparc (NASDAQ:SPRC) stock declined by 12.1% to $5.38. The company's market cap stands at $3.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.